Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been long for almost 3 years at approx $6-----I'm a bagholder on this one---U can't see this ????
R U OK ????????
All you have to do is post the info. That's what this international message board is for----Give us the info that you are referring to----Please !!!!!!
Why don't you post the info inside this URL so the rest of us don't have to offer up our e-mail address
to get it, and get a bunch of junk mail in return ???? You need to "pump" professionally & you will get results. Are you pc savvy??? Do you need help????
https://www.tickerreport.com/banking-finance/3900987/titan-pharmaceuticals-ttnp-shares-gap-up-to-0-38.htm
You should post the URL's of this info, so the "pump" looks legitimate instead of maybe just empty bull$hit.
When TTNP was at $6---Zacks projected $12----Here we are----The Breaburn debacle is mostly to blame----Maybe they got it right this time if they feed some Cognizine (brain food) to Bhonsle. Seems like TTNP should "take off" sooner or later.
volume is back down & mm's have stopped shuffling it back & forth----The "pumping" here was reeeeeely baad----Sounded like a bunch of "jive-ass $hitrappers"---Good professional pumping would have had a good effect, if you had also gone to the "other" Pump boards also. Volume back to somewhat normal means relative straightline for now & maybe for a long winter's sleep---or until some big Pharma co. leaks info about a takeover or buyout. or---CEO (Chief Extradork Officer) Bhonsle decides to release a PR, which could happen any day, or maybe not. How's that for certainty ?????
Wow! Out of sight !. You forgot---"Far Out"---"Right On"----& "Heavy Duty"---Glad to see you have some enthusiasm about this "rumor". Pumpers on this board are pretty sorry-----need to learn how to pump professionally, instead of sounding like "bubblegummers". Just my opinion---LOLOL !!!!! If this was handled professionally, we could go to "megadollar land".
It's not a news leak------It's a "rumor"----Which is-----"a currently circulating story or report of uncertain or doubtful truth."----Your guess is as good as anybody's. Could be some "pumpers" put this info out there.-----You'll kick yourself in the butt if you ignore it & it ends up being true. I've been sniffing around the inet about it & haven't been able to find anything else----But---Insider news ALWAYS leaks out---no exceptions. There's wives, husbands, aunts, uncles, relatives, good friends, goilfrens, boyfrens, etc, etc that always seem to get it, and then it leaks. Now ,---that is some good believable information---LOLOLOLOL !!!!!!!!! Don't lose any sleep over it tonight---It's only money $$$$$$
If Pfizer does take an interest in acquiring TTNP, they will be entering in to a new field in the drug world, to expand their repertoire of currently produced drugs. Could be a business boom.
Pfizer makes Preparation H, an anti-inflammatory product. Many of Pfizer's most recognizable brands can be found in a typical medicine cabinet, including Depo Provera, Lyrica, Dimetapp, Xanax and Chantix, an anti-nicotine drug. Pfizer brands also include Diflucan, Celebrex, Lipitor, and Ativan for anxiety.
https://rumormurmursbuzz.blogspot.com/2018/10/ceo-ian-read-to-confirm-pfizer-pfe.html
CEO Ian Read To Confirm Pfizer (PFE) Intent To Buyout Titan Pharmaceuticals (TTNP) As Probuphine Success Continues, Official PR Coming Prior To Thanksgiving
Rumors, Murmurs and Buzz presents the latest forecasts, predictions and rumors from the street on US equity markets. Enjoy the speculation but remember it's never wise to invest in any stock based on unsubstantiated speculative predictions or rumors.
Unprofessional pumpers !!!! They act like "bubblegummer" traders---problably using mommy's or daddy's trading account. Most of them can't even spell common words or have enough brain waves to to spit out a simple phrase.
TTNP pumpers: Go to these boards & pump ttnp "TO THE MOON"
1. BB's Stock Haven
2. MOMO'S BREAKOUT BOARD
3. Billionaire Boys Club Member Forum (BBCMF)
4. ORIONS Money Stocks
5. georgie18s House of Gain...
6. SMART MONEY GROUP
7. Franklin, Andrews, Kramer & Edelstein
8. $LEEK$CAPE’S 2018 HEMP, CBD & MARIJ
9. STOCKGOODIES PLAYS OF THE WEEK
10. "Savvy Trades and Investmen
Pumpin' here has never had any effect---You've got to go to the other "pump exposure" boards on Ihub---There's got to be at least a coupla dozen of them. Make the rounds, & get TTNP some exposure----- It's been a matter of "How low can you go" & we've been there---nowhere to go except up^^^^^^.. I believe Bonehead Bhonsle finally has some "staff" that will override his pathetic bull$hit & start to put us on the map---should have happened lonnnng ago. Also---Ripe for a takeover---either friendly, or hostile, if we get positive developments. I have a "Brass Buyout God"---& I'm going to polish him up again with a fresh can of "Brasso".
Scott Smith----The rest of the story, from "Fierce Pharma"
https://www.fiercepharma.com/corporate/celgene-coo-smith-leaves-suddenly-wake-ms-miss-and-other-immunology-failures
Go the "board"---click on "rikshot'----All my bs will come up---go to my posts for TTNP & read back----It's all there. Also---check my "personal info"---See why I like Selma Hayek--LOLOL
One member of the BOD bought a load (approx $140,000 worth as I remember) when it was approx 6 dollars----soooo----there goes that theory----At that time Zack's advisory said it was headed to $12. One of the BOD new hires was "let go" from a large Pharma Co for extreme incompetence & worse. Read back on the board to confirm this info (and more)
Here's how fast mm EDGA is transferring these shares---To where?---Or just showing up on Level 2
to legally account for them ?---S/P stays the same----???????? Almost always 500 shares at a time ????????
From: https://quotes.freerealtime.com/
Symbol:
TTNP
10/10/2018
Time Price Volume Market
12:46:03 0.211557 250 NDD
12:45:30 i 0.2136 3 NDD
12:45:13 0.2115 100 NDD
12:45:13 i 0.213925 57 NDD
12:44:59 0.2115 1800 NDD
12:44:58 i 0.2136 50 NDD
12:44:56 0.2115 3900 NDD
12:44:56 0.2115 500 EDGA
12:44:56 0.2115 500 EDGA
12:44:56 0.2115 500 EDGA
12:44:56 0.2115 300 EDGA
12:44:56 0.2115 160 EDGA
12:44:56 0.2117 340 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 500 EDGA
12:44:56 0.2117 100 EDGA
Refresh
Probably grabbed up by mm's---that's who makes $ on them----can be in limbo, traded between mm's and as they are accumulated, $ will flow into TTNP as a "loan payback" or any kind of a deal they could make----TTNP is desperate for $ or they wouldn't have secondaried. ( is that a word?) After the USA November election, opioid addiction will again become a more important priority than "last time", & any positives TTNP comes up with will put it in a better priority for a buyout----Either friendly, or leveraged. A good Pharma co could pick up this TTNP "fumble" & run with it.
How many were actually sold ????? Do you know???---How many are still in "limbo" & floating around between mm's & haven't found an acct to be in yet---whether it be an entity or private investor ????---How many are on "loan" in a mm's back pocket to be finally cashed out to TTNP ???---Do you think these deals are straight "in & out"?---Not these days---If SEC would try to trail it, it would take them forever. Things ain't like they used to be.
How do you know ????---Because they said that????? How do you explain almost 5 million shares when the avg daily volume used to be 100,000 or less---there's stuff going on behind the scenes with mm's & TTNP that we'll never know about----The SEC has too few attorneys to keep track of this stuff, when they are "shorthanded" & have bigger fish to fry. MM's can make all kinds of deals that are ????????. How do you explain almost 5,000,000 shares & the s/p is straightlined on the shart ????
This is a secondary offering of new shares by TTNP to raise $ for their big plans to get their TTNP awareness program started, so that the proneura platform will start making $. R U OK ???---or just not aware of what's happening???? Maybe you should read back on the board & get straightened out.
TTNP is verrrry hungry for the $, so their mm is saying "Let's make a deal". Makes me wonder how many shares will actually go out, and what kind of entity is scarfing them up. 4 million let out today, so that brings in about $800,000 for Titan. I hope it gets used properly, instead of the old "upside down & backwards" philosophy of Bhonsle's.
U may be right, but I think the bulk of this board would say you should stick to trading weed until we can see what is actually happening here---Bhonsle has proved incompetent.
Gotcha Turks-----Sounds like all these millions needed to keep 1/2 a mil per year going to Bhonsle & his partner----It just doesn't "sound" good.
Titan Pharmaceuticals Prices $9,500,000 Public Offering
PR Newswire
September 20, 2018, 5:30 PM PDT
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) ("Titan" or the "Company"), a commercial stage company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced the pricing of an underwritten public offering with expected total gross proceeds of $9,500,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.) Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)
The securities offered by the Company consist of (i) Class A Units consisting of 5,100,000 shares of our Common Stock and Warrants to purchase 5,100,000 shares of Common Stock, and (ii) Class B Units consisting of 8,225 shares of our Series A Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 32,900,000 shares of Common Stock, and Warrants exercisable for the number of shares of Common Stock into which the shares of Series A Convertible Preferred Stock are convertible. The Warrants will have an exercise price of $0.25, will be exercisable upon issuance and will expire five years from the date of issuance. The Company has granted the underwriters a 45-day option to purchase additional shares of Common Stock and/or additional Warrants to purchase shares of Common Stock, in amounts up to 15% of the Common Stock, Warrants and/or Common Stock issuable upon conversion of the Series A Preferred included in the Class B Units sold in the offering.
The offering is expected to close on September 25, 2018, subject to customary closing conditions.
A.G.P./Alliance Global Partners is acting as the sole book-running manager for the offering.
CIM Securities, LLC is acting as a co-manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission (the "SEC") and was declared effective on September 20, 2018.
The offering will be made only by means of a prospectus. A copy of the prospectus relating to the offering may be obtained, when available, by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2006 or email: prospectus@allianceg.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Approved by the FDA in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology also has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACTS:
Sunil Bhonsle,
President & CEO
(650) 244-4990
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
Every time a new buy comes in, MM's are siphoning off the $---MM's NDD, Arca, & NASDAQ are selling off thousands of shares that I believe are for the brokers of the "big holders" with residual shares, connected to the Braeburn debacle.
------------------------------------------------------------------------
https://quotes.freerealtime.com/quotes/TTNP/Time&Sales
Time and Sales for Titan Pharmaceuticals Inc. (TTNP) Sep 20, 2018
17:28:23 t 0.5001 2100 NDD
17:26:23 i 0.5001 30 NDD
17:26:17 i 0.50 1 NDD
17:18:07 i 0.5001 5 NDD
16:37:39 t 0.5001 1000 NDD
16:36:18 t 0.5001 234 ARCA
16:36:18 t 0.5001 100 ARCA
16:34:16 t 0.5001 1010 ARCA
16:34:16 t 0.5001 100 ARCA
16:32:26 t 0.5001 1800 NDD
16:31:53 t 0.5001 500 NDD
16:31:28 t 0.5001 400 NDD
16:27:45 t 0.5001 4800 NDD
16:25:03 t 0.5001 300 NDD
16:10:36 t 0.5001 170 NASDAQ
16:10:36 t 0.5001 530 NASDAQ
16:10:36 t 0.5001 2100 NASDAQ
16:10:36 t 0.5001 1000 NASDAQ
16:10:36 t 0.5001 1000 ARCA
There's no telling what's "lurking" in the background. As this opioid problem keeps getting worse (and more worser) and the TTNP technology gains awareness, we could get a suprise from another pharma co. that could deal with this in a more professional & businesslike $ manner.
The lower this goes, the more value it has to a buyout or takeover entity.
A million & a half shares traded & & s/p only up 2 cents---Means approx 750,000 shares sold off. Residual shares are still sellin' off----Need to put another hex on Braeburn & friends.
https://finance.yahoo.com/news/titan-awarded-nida-grant-development-110000318.html?.tsrc=applewf
Titan Awarded NIDA Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse
PR Newswire
September 10, 2018, 7:00 AM EDT
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has been awarded a two year grant of approximately $6.7 million from the National Institutes of Health's National Institute on Drug Abuse (NIDA) for the development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification. The grant provides approximately $2.7 million for the project from now through August 31, 2019, with the balance to be funded over the subsequent year, subject to satisfactory project progress, fund availability and certain other conditions.
Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)<img alt="Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)" src="https://s.yimg.com/ny/api/res/1.2/CrgaJJ080jpVh2J3vzcjnQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIxMi44/https://s.yimg.com/uu/api/res/1.2/6qFqntHSDOKb9ELU3aRHSg--~B/aD0xMzM7dz00MDA7c209MTthcHBpZD15dGFjaHlvbg--/http://globalfinance.zenfs.com/en_us/Finance/US_AFTP_PRNEWSWIRE_LIVE/Titan_Awarded_NIDA_Grant_For-263fd05d651998a2057a9f8a1bcbb23f" class="caas-img">
Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)
"NIDA previously provided funds for an important Phase 3 trial of our approved product, Probuphine®, and we are grateful for this additional vote of confidence in our ProNeura technology as well as our ability to execute on another program for the treatment of opioid addiction," said Titan's Chief Scientific Officer and Principal Investigator of the project, Dr. Kate DeVarney.
Titan was awarded this grant following an in-depth evaluation by NIDA of the Company's proposed research for scientific and technical merit. The grant provides approximately half of the expenses associated with the completion of non-clinical studies which, if successful, are expected to support the Company's submission of a Nalmefene six-month implant Investigational New Drug Application to the U.S. Food and Drug Administration (FDA). Titan retains full commercial rights to the Nalmefene implant product.
"This NIDA grant serves as further validation of the importance of long-term treatment options in addiction medicine," said Titan's President and CEO, Sunil Bhonsle. "As we continue to make progress in transitioning to a commercial company marketing Probuphine, we believe that our Nalmefene implant has the potential to become an important addition to our product portfolio for addressing opioid addiction, a global health emergency."
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Approved by the FDA in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology also has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACTS:
Sunil Bhonsle,
President & CEO
(650) 244-4990
Look what's just happened at Tesla & Nike----Sometimes the CEO's are the worst enemy of their own company. There has to be a"special word" for these actions----What iz it ????? LOLOL
Prospectus, secondary offering & dilution are going to raise $17.9 mil ?????------or even half that much under current "conditions" ?????????
Where is the $17.9 million going to come from ???????
https://www.bizjournals.com/sanfrancisco/news/2018/08/20/opioids-titan-pharmaceuticals-ttnp-probuphine.html?ana=yahoo&yptr=yahoo
Soooo quiet here-----Doesn't anyone have some info about what went on at the shareholder's meeting ????
Tomorrow---Shareholder's meeting brings either good tidings, or dire straits.
CBS News investigation finds recruiters pay struggling addicts to get high-priced surgery
NEW YORK -- A CBS News investigation has uncovered an industry of recruiters taking advantage of struggling addicts.
The scheme lures addicts into getting a non-FDA approved Naltrexone implant, which releases medication to block opiate receptors in the brain, which makes it difficult for drug users to feel the effects of opioids. But as "CBS Evening News" anchor Jeff Glor reports, some patients are getting under-the-table cash payments from recruiters to get the surgery. Doctors can earn up to $30,000 from each procedure from insurance companies.
Industry insiders revealed to CBS News that some doctors hire marketers to generate business and some employ recruiters to pay patients to get the implant. One former recruiter says they preyed on people at their weakest moments.
"I would find anybody who was vulnerable," says John, a former heroin user and recruiter, tells CBS News. "I said, 'Hey, you know this really helped me out, this is how I got sober,' even if I wasn't sober when I was saying this."
Debbie Berry, of Ashland, Missouri, said her son went to California to get help with a heroin addiction. One day, Berry heard from her son, saying he found something to stay clean.
"He said i'm going to get an implant put in. Your insurance will pay for it," Berry said.
But she did not know he was getting paid for the surgery.
https://www.cbsnews.com/news/cbs-news-investigation-recruiters-pay-struggling-addicts-to-get-high-priced-surgery/
At 1:52 PM EDT----Up 12 cents on 26,000 shares----See how fast this moves up when the #*^%$#*&^+ residuals aren't selling off ? Maybe the HEX on Braeburn is working it's magic forces--LOLOL.
The annual meeting of stockholders of Titan Pharmaceuticals, Inc. (“our company, “Titan,” “we,” “our,” or
“us”) will be held at our executive offices at 400 Oyster Point Boulevard, Suite 505, South San Francisco,
California 94080 on Tuesday, August 7, 2018 at 9:00 a.m. local time for the following purposes:
• to elect a board of eight directors;
• to approve an amendment to our 2015 Omnibus Equity Incentive Plan to increase the number of shares
of common stock reserved for awards from 2,500,000 to 3,500,000;
• to ratify the appointment of OUM & Co. LLP as our independent registered public accounting firm for
the fiscal year ending December 31, 2018; and
• to consider and take action upon such other matters as may properly come before the meeting or any
adjournment thereo
It needs proper exposure and to be "highly regarded" by the entities that could & should be using it to make it an opioid rehabilitation & financial success.
Disgruntled residual shares still selling off----We should be ^ 1.50 by now. Some body----Roll the chicken bones & put a *&%$#^&* Hex on Braeburn.
_________________________________________________________________________
https://www.spellsofmagic.com/spells/spiritual_spells/banishing_spells/3779/page.html
buprenorphine to manage opioid use disorders.Probuphine is the first buprenorphine implant.
http://www.foxnews.com/opinion/2018/07/07/dr-marc-siegel-opioid-crisis-has-solution-here-it-is.html